Navigation Links
Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
Date:5/26/2009

ROCKVILLE, Md., May 26 /PRNewswire/ -- Theranostics Health, Inc. (TH) is pleased to announce its involvement in a five-year clinical research study funded by the Susan G. Komen Foundation. TH's collaborator, Duke University, was the recipient of a Promise Grant, part of over $25 million of investment by the foundation in 2009 to further the development of new prevention and treatment options for breast cancer.

The Susan G. Komen for the Cure(R) is a nonprofit organization dedicated to improving the lives of breast cancer patients through funding groundbreaking research. Since its inception nearly 30 years ago, the foundation has invested over $400 million. This year alone, grants will go to 54 universities and hospitals in 26 states and one foreign country, all for addressing the challenges associated with breast cancer.

Theranostics Health has been collaborating with researchers at Duke University as part of the collaboration agreement established in May 2008. Studies conducted by Theranostics Health with Dr. Victoria Seewaldt, MD, a Duke investigator, have provided the underlying rationale and preliminary data in support of the research proposed for the Promise Grant. Dr. Seewaldt is dedicated to discovering and developing new prevention and treatment strategies for each of her patients afflicted with breast cancer.

Theranostics Health will use its pathway mapping platform to measure signaling pathway activation in hundreds of key signaling proteins directly from randomly obtained periareolar breast fine-needle aspiration to assess individual response to chemoprevention in high-risk patients. This information can be used to develop a rapid test that matches the right prevention agent to each patient based on the biology of abnormal cells in each woman's body.

"The power of this new technology is that it gives us the possibility of tracking how a woman is or is not responding to a prevention drug," said Dr. Victoria Seewaldt. "If this project is successful, it will pave the way for quickly testing the effectiveness of prevention drugs as well as biological response to exercise."

"We are very pleased to have the opportunity of working with first-class research clinicians like Dr. Seewaldt. We share the same vision as Dr. Seewaldt in that each patient's tumor is different and an individualized assessment and approach is needed to effectively prevent and treat diseases," noted Dr. Danong Chen, President and CEO of Theranostics Health.

About Theranostics Health

Theranostics Health (TH) is a privately held company founded in 2006. Its proprietary technology platform includes fixative reagents, Laser Capture Microdissection (LCM), and Reverse Phase Protein Microarray (RPMA). TH's proprietary fixatives are developed to both preserve cell morphology and fix the state of cellular activities for molecular analysis. LCM is used to isolate specific cell populations from many different types of cells usually present in a clinical biopsy. Therefore, information derived from subsequent molecular assays is specific to that cell population. RPMA enables sensitive, quantitative, calibrated, multiplexed analysis of cellular proteins from a limited amount of starting materials, such as clinical specimens. TH has an exclusive license from the National Institute of Health (NIH) to commercialize microdissection, including LCM, combined with protein analysis for cancer diagnostics and companion diagnostics. While providing research and development services to pharmaceutical companies and academic institutions for efficient and effective target discovery and drug development, TH is developing clinical tests, enabling physicians to tailor optimized therapies for patients based on the biomarker profile of each patient's disease specimen. The technology, developed by the company's scientific co-founders, Drs. Emanuel Petricoin and Lance Liotta, was first published in 2001 and in the past 2 years has been used in studies published in more than 50 peer-reviewed journals and presentations. TH's technology was also successfully used in NCI-sponsored clinical trials. For more information please email info@theranosticshealth.com or visit http://www.theranosticshealth.com/.


'/>"/>
SOURCE Theranostics Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
2. Theranostics Health Receives Green Light to Perform Clinical Testing
3. American Lung Association Offers Simple Tips to Protect Public Health and Minimize H1N1 Flu (Swine Flu) and Seasonal Flu Transmission
4. New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health
5. Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels
6. MedNet Solutions Certified to Score SF-12v2 Health Survey
7. Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase
8. First Human Study to Show Sun Chlorella A Supports Heart Health
9. Nations Laboratory Response Network Marks First Decade of Protecting Public Health
10. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
(Date:6/8/2017)... Responding to Heath Ledger,s father,s recent call for ... Chris Cornell in May, the mental health watchdog group, ... psychiatric drug side effects search engine ... risks. The father of the late actor ... has called for tighter rules on prescription drugs. Speaking at ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. ... New York, has recently begun offering three new minimally invasive procedures to patients ... procedures and reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat ... new videos highlight the importance of correctly using a meat thermometer. The videos ... done extensive research on consumer food safety habits. Dr. Bruhn explains the variety ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ... the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people ... the Biggert-Waters Act was enacted to reflect the actual risk in flood zone ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit Advisors ... Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, Florida, ... risk while tailoring optimized benefit packages that strengthen the relationship between employer and ...
Breaking Medicine News(10 mins):